Background
==========

Aniridia is a human congenital eye malformation with a population frequency of 1 in 60,000--100,000 \[[@B1]\]. Mutations in the transcription factor gene *PAX6*cause blindness \[[@B2]\] through a spectrum of ocular manifestations among which aniridia and most probably foveal hypoplasia are the major signs \[[@B3]-[@B5]\].

The human *PAX6*gene located on chromosome 11p13, was isolated by positional cloning as a candidate gene for aniridia \[[@B6]\]. Most of the point mutations in this gene will lead to premature truncation of protein \[[@B7]\]. Aniridia occurs due to decreased dosage of the *PAX6*gene, which controls early events in the morphogenesis of the eye and brain \[[@B8],[@B9]\]. It exists in both sporadic and familial forms. One third of the aniridia cases are sporadic and two thirds are familial \[[@B3]\]. The sporadic cases can be part of WAGR syndrome (Wilms\' tumor, aniridia, genitourinary anomalies, mental retardation), which is caused by hemizygous deletions of the *PAX6*and *WT1*genes. The *PAX6*gene spans 22 kb in size and consists of 14 exons and 13 introns. The translation initiation codon is in exon 4 and the termination codon is in exon 13 \[[@B8]\]. The human *PAX6*gene has paired box and homeobox motifs and encodes a highly conserved protein of 422 amino acids among metazoans. The function of the PAX6 protein is crucial for the development of human eye. The paired domain and the homeodomain are the two DNA binding domains, which are separated by a linker segment (LNK) and followed by a C-terminal region rich in proline, serine and threonine (PST). The presence of two DNA binding domains in *PAX6*strongly suggests that the protein functions as a transcription factor to regulate the expression of other genes during embryogenesis \[[@B10],[@B11]\].

Mutations in the *PAX6*gene have been reported in a growing number of aniridia patients and patients with other ocular malformations \[[@B12],[@B5]\]. The mutations are scattered throughout the gene. The vast majority of mutations reported so far are nonsense mutations, frameshift mutations or splicing errors that are predicted to cause premature truncation of the PAX6 protein, causing haploinsufficiency \[[@B12]\].

Even though the *PAX6*gene has been studied in various ethnic populations, Indian aniridia mutations are not well studied. For this reason we decided to study *PAX6*variations in an Indian population. Here we report five coding mutations of which three are novel mutations in sporadic cases of aniridia in south Indian population. Our study supports the hypothesis that the mutations in the human *PAX6*gene appear to correlate with classic aniridia phenotype.

Methods
=======

Clinical evaluation
-------------------

This was done with informed consent and in accordance to the tenets of the Declaration of Helsinki. Twenty-eight members of six unrelated aniridia families and 60 healthy normal controls were recruited for this study. Examination included slit lamp, gonioscopy, IOP measurement and biomicroscopy.

Mutation screening and sequence analysis
----------------------------------------

Total genomic DNA was isolated by the salt precipitation method from peripheral blood \[[@B13]\]. The amplification of exons 4--13 to detect *PAX6*gene mutations was carried out in a 20 μl reaction mixture containing 100 ng of genomic DNA, 100 pM of each primer, 1X PCR buffer (Promega USA) and 0.5 U of Taq DNA polymerase (Promega USA). The coding region of the human *PAX6*gene was amplified with previously published primers \[[@B8]\]. PCRs were carried out in a MJ Research thermocycler for 35 cycles, consisting of 1 min at 95°C for denaturation, 1 min at 58°C for primer annealing and 10 min at 72°C for primer extension. Single strand conformation polymorphism analysis was carried out in 10% polyacrylamide with or without 2.5% glycerol as previously described \[[@B14]\]. The PCR products were sequenced to confirm the exact nucleotide change by ABI prism (Microsynth, Switzerland).

Allele specific clones
----------------------

The superimposed mutant PCR products were amplified and cloned into the pGEM-T vector (Promega USA). Each transformed colony contains the mutant allele or the normal allele \[[@B15]\]. Exon-specific PCR-SSCP was performed from the transformed colonies. Two PCR reactions were performed in parallel. In the first reaction the 5\' primer is complementary to the wild type sequence and in the second reaction the 5\' primer is complementary to the mutant sequence. The elongation occurs only when primers and target sequence match completely, so only one allele of either mutant or wild type DNA is amplified \[[@B16],[@B17]\]. The plasmids were used as templates in amplification to generate PCR products for SSCP. The SSCP banding pattern was used to select allele-specific clone for sequencing (data not shown). The restriction digestion was performed for exon 6 with RsaI enzyme to differentiate between mutant and normal allele and visualized on a 2.5% agarose gel.

Results
=======

We used the SSCP technique to search for mutations in exons 4--13 of the *PAX6*gene (OMIM 106210) in probands with aniridia and normal controls. The clinical information for each sporadic aniridia patient is given in Table [1](#T1){ref-type="table"}. Altered mobility shifts detected by SSCP were confirmed by repeating two or three times. All the mutants we describe here (except two that were analysed by direct sequencing) were cloned in to the pGEM-T vector followed by allele-specific PCR to pick up the correct clone using the plasmid DNA as template because the genomic PCR gave superimposed signals. Sequencing reactions were then carried out. Although this plasmid based SSCP analysis is time consuming, it reliably allows identification of each allele. The mutant sequences are deposited in Genbank \[[@B18]\]. (**AY307164, AY289493, AY337853, AY337852, AY342394**) and also in the PAX6 Allelic Variant database \[[@B19]\]. The summary of our findings is given in Table [2](#T2){ref-type="table"}.

###### 

Clinical and common phenotypes associated with the aniridic probands

  Proband   Age/ Sex   Best Vision   Refractive Error   Nystagmus        Keratopathy   Iris   Cataract   Glaucoma   Optic nerve Hypoplasia   Macular Hypoplasia   Glaucoma                                                                                
  --------- ---------- ------------- ------------------ ---------------- ------------- ------ ---------- ---------- ------------------------ -------------------- ---------- ---- ---- ---- ---- ---- ---- ------------------- -------------------- ----- -----
                                                                                                                                                                                                           Medical treatment   Surgical treatment         
                                                                                                                                                                                                                                                          
                       RE            LE                 RE               LE                   RE         LE                                  RE                   LE         RE   LE   RE   LE   RE   LE   RE                  LE                   RE    LE
                                                                                                                                                                                                                                                          
  28--1     17 yrs/F   6/24          6/24               +7.0             +7.0          NA     \+         \+         A                        \+                   \+         \+   \+   \-   \-   NA   NA   \+                  \+                   4,1   1,2
  27--1     8 yrs/M    6/60          6/60               -1.0 -1.0 × 90   -1. 50        \+     \-         \-         A                        \-                   \-         \+   \+   \-   \-   \+   \+   \+                  \+                   3     3
  10--1     13 yrs/M   PL            HM                 NI               NI            \+     \-         \-         A                        \+                   \+         NA   \+   \-   \-   NA   NA   \-                  \+                   5     \-
  21--1     2 mon/M    \-            \-                 \-               \-            \+     \-         \-         R                        \-                   \-         \-   \-   \-   \-   \+   \+   \-                  \-                   \-    \-
  16--1     15 yrs/M   6/60          HM                 NI               NI            \+     \+         \+         R                        \+                   \+         \+   \+   \-   \-   \+   \+   \+                  \+                   \-    \-
  18--1     30 yrs/M   PL            PL                 NI               NI            \+     \+         \+         R                        \+                   \+         \+   \+   \-   \-   NA   NA   \+                  \+                   \-    \-

RE-Right Eye; LE-Left Eye; HM-Hand Movement; PL-Perception of Light; A-Absent; R-Remnant; NA-Not Available; NI-No Improvement; 1-Trabeculectomy; 2-Cyclocryocoagulation; 3-Awaiting cataract surgery; 4-Cataract surgery; 5-Surgery for Retinal detachment.

###### 

Molecular analysis of *PAX6*mutations with their predicted products.

  **Proband**   **Exon/ Intron**   **Systematic Name**   **Codon**   **Domain**   **Type of Mutation**                            **Predicted amino acid change**   **References**
  ------------- ------------------ --------------------- ----------- ------------ ----------------------------------------------- --------------------------------- ----------------
  23--1         9                  c.1080C\>T            240         HD           Nonsense                                        Arginine to stop Codon            \[14\]
  14--1         10                 c.1180insA            273         PST          Frame shift Due to insertion                    Premature termination             \[14\]
  28--1         6                  c.715ins5             118         PD           Frame shift due to insertion with duplication   Addition of two amino acids       Present Report
  27--1         10                 c.1201delA            280         PST          Deletion                                        Termination codon at Exon 12      Present Report
  10--1         8                  c.901delA             180         LNK          Deletion                                        Premature termination at exon 8   Present Report
  21--1         5                  c.482C\>A             40          PD           Nonsense                                        Cysteine to stop codon            Present Report
  16--1         7                  c.830G\>A             156         LNK          Nonsense                                        Tryptophan to stop codon          Present Report
  18--1         intron 9           IVS 9-12C\>T          \--         HD           Transition                                      Neutral polymorphism              Present Report

PA-Paired domain; HD-Homeo domain; LNK-linker region; PST-Proline serine threonine region.

Novel mutations in the *PAX6* gene
----------------------------------

In proband 28--1 the plasmid-based clones were sequenced, revealing an insertion with duplication of five bases at position 715 in codon 118 (c.715ins5), which resulted in a novel frameshift mutation in *PAX6*gene. The phenotypic expression of aniridia is shown in Fig. [1A](#F1){ref-type="fig"}. The pedigree and the SSCP pattern and the unusual band shift detected in exon 6 is given in Fig. [2A](#F2){ref-type="fig"}. The insertion of 5 bases duplicates the cDNA sequence (Genbank **M93650**) from bases 711--715 of *PAX6*gene (Fig. [3A](#F3){ref-type="fig"}). *De novo*change was observed at position 715 in the proband, which is a site for most common reported mutations \[[@B20]-[@B22]\]. The PCR product of 300 bp was digested with RsaI enzyme, which resulted in a 220 bp and 80 bp products in normal whereas the mutant gives 220 bp and 85 bp (data not shown).

![Phenotypic expression of aniridia with *PAX6*gene mutation. The aniridic probands showed typical features of sclerocornea with nystagmus in proband 28--1 (A); Foveal hypoplasia in proband 27--1 (B); Ptosis, microcornea with dislocated cataractous lens in proband 10--1 (C); Ectopia lentis in proband 16--1 (D).](1471-2350-5-9-1){#F1}

![The pedigree and SSCP analysis of aniridia probands. Pedigree shows the affected (arrow) and unaffected individuals to the corresponding SSCP gel; unaffected family members (1,2,3), filled square (male) and filled circle (female) are affected members. N- unrelated healthy controls. Arrow indicates the mobility shift in SSCP gel.](1471-2350-5-9-2){#F2}

![Electropherogram showing the mutant and normal controls of *PAX6*gene. Chromatogram showing the sequence variations in *PAX6*gene is indicated by arrow. Plasmid based sequencing revealed c.715ins5 in 28--1 (A), c.1201delA in 27--1 (B), c.901delA in 10--1 (C) and IVS9-12C\>T in 18--1 (F). Direct sequencing revealed c.482C\>A in 21--1 (D), and c.830G\>A in 16--1 (E), N-Normal control, Box- duplication of sequence.](1471-2350-5-9-3){#F3}

The phenotypic expression of proband 27--1 is shown in Fig. [1B](#F1){ref-type="fig"}. The patient showed an abnormal band shift when compared with the unaffected family members in SSCP analysis (Fig. [2B](#F2){ref-type="fig"}). The plasmid-based sequencing results showed a deletion of single base at position 1201; codon 280 (c.1201delA) in PST region is shown in Fig. [3B](#F3){ref-type="fig"}. The deletion of adenosine residue at exon 10 predicts the premature truncation at exon 12 alters the conservation of amino acids from serine at codon 280. The proband had another unique change, A\>G at position 1239 (c.1239A\>G), 38 bases downstream of the deletion on the same allele in exon 10 (data not shown). The two changes were identified by allele specific PCR with repeated sequencing of different clones, since the direct sequencing of genomic PCR gave superimposed signals. Two changes on one allele have been previously reported \[[@B23]\].

The morphology of aniridia due to deletion in the LNK region is shown in Fig. [1C](#F1){ref-type="fig"}. In proband 10--1, an obvious bandshift on the SSCP gel was seen (Fig. [2C](#F2){ref-type="fig"}), which on sequencing (plasmid-based) revealed the mutation c.901delA in the coding region of exon 8 at codon 180 (Fig. [3C](#F3){ref-type="fig"}). The single adenosine residue deletion results in a frameshift mutation, generating a stop codon within the LNK region. The consequences of this mutation would be to produce a truncated protein, lacking the homeobox domain.

The PCR-SSCP followed by direct sequencing revealed a nucleotide substitution in proband 21--1 (Fig. [2D](#F2){ref-type="fig"}). The heterozygous transversion (C\>A) was observed at position 482 (c.482C\>A), which disrupts the cysteine (TGC) to stop (TGA) at codon 40 (C40X) in exon 5 in the paired domain (Fig. [3D](#F3){ref-type="fig"}). As a consequent, the nonsense mutation C40X produced a truncated protein, lacking the LNK, homeobox and PST regions.

Another nonsense mutation (W156X), which was detected in proband 16--1, resulted in expression of aniridia phenotype (Fig. [1D](#F1){ref-type="fig"}). The SSCP gel analysis (Fig. [2E](#F2){ref-type="fig"}), and the chromatogram revealed G\>A transition at position 830 (c.830G\>A) which changes the tryptophan (TGG) to stop (TGA) at codon 156 in LNK region (Fig. [3E](#F3){ref-type="fig"}). We report these nonsense mutations for the first time in a south Indian population, although they have been reported before in French population \[[@B24],[@B25]\].

*PAX6* gene polymorphism in aniridia
------------------------------------

SSCP analysis of exon 10 in the family of proband 18--1 is shown in Fig. [2F](#F2){ref-type="fig"}. The sequencing analysis showed an intronic change at position -12 of intron 9 (IVS9-12C\>T) is shown in Fig. [3F](#F3){ref-type="fig"}. This polymorphism has been previously reported in Indian \[[@B26]\] and Caucasian \[[@B27]\] populations. Even though the mutation falls in the splice acceptor site of exon 9 it seems to be a neutral polymorphism. The unaffected parents have normal sequences in all the exons of *PAX6*gene.

Discussion
==========

Mutations of the *PAX6*gene are known to cause many cases of inherited and sporadic aniridia. The *PAX6*gene is clearly vital for the normal development of the eye \[[@B28]\]. The phenotype presumably results from heterozygous insufficiency such that if only one copy of the gene is active insufficient protein is produced to support normal development of the eye. The protein products of the mutant genes could theoretically have DNA binding activity and compete with the wild type protein. However, the fact that aniridia caused by intragenic mutation is phenotypically indistinguishable from aniridia caused by deletion of entire *PAX6*gene makes it likely that the mutant alleles are in fact null alleles \[[@B4],[@B25]\].

The pathological mutations will be found throughout the gene including the promoter and the other regulatory regions. In these patients all the mutations if translated, would result in truncated protein products. The translated proteins would be unable to carry out normal PAX6 function because functional domains are deleted. The two DNA binding domains are important for the normal activity of the protein \[[@B7],[@B10]\]. Proband 27--1 with c.1201delA also has another change, c.1239A\>G downstream of the deletion, however its impact on transcriptional product is unknown. The downstream mutation may be less important because it is likely that the other mutation (c.1201delA) is the one responsible for aniridia. Though the two nonsense mutations C40X and W156X were previously reported in other population, we report for the first time in aniridic patients in south Indian population and thus it could be a recurrent mutation.

The change in the splice acceptor region of intron 9 (IVS9-12C\>T) is a neutral polymorphism that has been observed before and the C\>T substitution in the splice acceptor consensus sequence is not predicted to have any effect on function \[[@B29]\]. In addition, other studies with this change in patients with aniridia have a clear pathological mutation elsewhere in the gene \[[@B19]\]. It is likely that the patient 18--1 might have a pathological mutation elsewhere in the *PAX6*gene, perhaps in one of the *cis*regulatory sequences.

Analysis of *PAX6*mutants showed that the pathogenicity effects appear to be loss-of-function mutations, which leads to aniridia (Fig. [1](#F1){ref-type="fig"}) and other variable phenotypes \[[@B25]\]. The mutations showed varying phenotypic severity of the disease. The proband with c.715ins5 mutation showed the presence of sclerocornea with nystagmus in both eyes. A similar phenotype (Foveal hypoplasia) was observed in probands with c.1201delA and c.482C\>A. Proband 10--1 with c.901delA revealed ptosis, microcornea with dislocated cataractous lens. Marfan syndrome and ectopia lentis was observed in both eyes of the proband 16--1 with c.830G\>A. Even though Marfan syndrome is rarely associated with aniridia \[[@B3]\] we observed the syndrome in the proband. The peripheral corneal pannus with bullous keratopathy and corneal ectasia was observed in IVS9-12C\>T. It is worthwhile to note that all the mutations observed in this study are associated with common phenotypes.

Our data provide evidence that some of the *PAX6*gene mutations identified in aniridia patients lead to disruption of *PAX6*gene expression due to the premature termination and most of which are assumed to cause loss of activity of one allele \[[@B30]\]. The Nonsense mutations would be predicted to result in truncated proteins due to a mechanism called \'nonsense-mediated decay\' which degrades mRNAs containing premature stop codons (nonsense mutations). Therefore, *PAX6*mRNAs that contain nonsense mutations would be degraded and would not be translated \[[@B31]\]. Identifying new mutations contributes valuable information for carrier detection for specific effect mutation and genetic counseling.

Conclusions
===========

In summary we add three novel frameshift mutations, two nonsense mutations and a polymorphism to the existing spectrum of *PAX6*mutations in south India in patients with the characteristic phenotype of aniridia. The two nonsense mutations are identified for the first time in south Indian population, which is not a well-studied ethnic group. Our genetic analysis provides further evidence that haploinsuffiency of the *PAX6*gene causes the classic aniridia.
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